Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs

Jun Wu; Xing Zhou; Yuanqing Tan; Liu Wang; Tianda Li; Zhongwen Li; Tingting Gao; Jiaqi Fan; Baojie Guo; Wei Li; Jie Hao; Xianguang Wang; Baoyang Hu

doi:10.1111/cpr.12944

Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs

Cell Prolif. 2020 Dec;53(12):e12944. doi: 10.1111/cpr.12944. Epub 2020 Oct 26.

Authors

Jun Wu^{1

2

3}, Xing Zhou⁴, Yuanqing Tan^{1

2}, Liu Wang^{1

2

3

5}, Tianda Li^{2

3}, Zhongwen Li^{1

2

3}, Tingting Gao^{1

2

3

5}, Jiaqi Fan^{1

2}, Baojie Guo^{1

2

3

5}, Wei Li^{1

2

3

5}, Jie Hao^{1

2

3}, Xianguang Wang⁴, Baoyang Hu^{1

2

3

5}

Affiliations

¹ Department of National Stem Cell Resource Center, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
² Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China.
³ State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
⁴ Wuhan Jinyintan Hospital, Wuhan, China.
⁵ University of Chinese Academy of Sciences, Beijing, China.

No abstract available

Keywords: COVID-19; CT; IMRCs; pulmonary fibrosis.

Publication types

Clinical Trial, Phase I
Letter

MeSH terms

Adult
Aged
COVID-19 / complications
COVID-19 / pathology*
COVID-19 / virology
Cell Differentiation
Female
Human Embryonic Stem Cells / cytology*
Human Embryonic Stem Cells / metabolism
Humans
Injections, Intravenous
Male
Middle Aged
Pulmonary Fibrosis / etiology
Pulmonary Fibrosis / therapy*
SARS-CoV-2 / isolation & purification
T-Lymphocytes, Regulatory / cytology
T-Lymphocytes, Regulatory / metabolism
T-Lymphocytes, Regulatory / transplantation*

Publication types

MeSH terms

Grants and funding